Sagimet Biosciences Inc.
$6.86
+1.3%Sagimet Biosciences Inc., a clinical-stage biopharmaceutical company, develops therapeutics called fatty acid synthase (FASN) inhibitors for the treatment of diseases that result from dysfunctional lipid metabolism pathways. Its lead drug candidate is Denifanstat, a FASN inhibitor for the treatment of nonalcoholic steatohepatitis and acne. The company is also developing TVB-3567, a FASN inhibitor for the treatment of various types of cancers. The company was formerly known as 3-V Biosciences, Inc. and changed its name to Sagimet Biosciences Inc. in August 2019. Sagimet Biosciences Inc. was incorporated in 2006 and is headquartered in San Mateo, California.
At a Glance
Live SnapshotIntrinsic Alpha Methodology
Thesis Lenses
Signal
Medium confidenceValuation multiple is compressed (P/E -4.3).
Valuation inputs: P/E -4.3, earnings yield N/A, momentum +1.3%.
If multiples stay elevated while momentum fades, downside repricing risk rises.
Driver
High confidenceReturn profile is soft (ROE -45.8%, ROIC -51.0%).
Profitability stack: net margin 0.0%, ROE -45.8%, ROIC -51.0%.
Quality deterioration often appears in margins before it shows up in headline EPS.
Risk
High confidenceRisk profile is balanced but has notable pressure points to monitor.
Risk factors: liabilities/assets +4.4%, momentum +1.3%, net margin 0.0%.
Higher leverage with weak momentum and thin margins can amplify drawdown severity.
Sagimet Biosciences Inc. Market vs Earnings Trajectory
Loading price and EPS data...
Sagimet Biosciences Inc. Fair Value Envelope
Sagimet Biosciences Inc. Profit Bridge
Profitability Analysis
Sagimet Biosciences Inc. Cash Conversion Engine
Cash Flow Quality Analysis
FCF Conversion Rate
Strong cash conversion. Most reported earnings translate into actual cash flow, suggesting solid fundamentals.
FCF Growth Trend
Declining FCF warrants attention. Investigate whether due to temporary factors or fundamental deterioration.
Working Capital Impact
Minimal working capital impact on FCF. Changes in operating assets and liabilities well-managed.
Cash Flow Quality Insight
Working capital strain: Significant cash tied up in operations. Monitor receivables collection, inventory turns, and payment terms to optimize cash conversion cycle.
Sagimet Biosciences Inc. Funding & Solvency Profile
Financial Health Analysis
Current Ratio
Excellent liquidity position. The company can easily cover its short-term obligations with substantial cushion.
Debt-to-Equity Ratio
Conservative capital structure. The company relies primarily on equity financing, indicating low financial risk.
Working Capital
Strong working capital position provides significant operational flexibility and financial cushion.
Asset Composition
Asset-light business model with high liquidity. Majority of assets are easily convertible to cash.
Financial Health Insight
Strong financial foundation: Excellent liquidity combined with conservative leverage suggests the company is well-positioned to weather economic uncertainties and fund growth opportunities.
Sagimet Biosciences Inc. Street Expectations Map
Wall Street analysts project that SGMT stock may rise significantly over the coming 12 months. The consensus 1-year price target stands at 8.00, with estimates ranging from a low of 8.00 to a high of 8.00.
The consensus 1-year price target stands at 8.00, with estimates ranging from a low of 8.00 to a high of 8.00.
Analyst Consensus Analysis
Upside Potential
Strong upside potential. Consensus indicates attractive return opportunity with favorable risk-reward profile.
Analyst Agreement
High analyst agreement. Narrow target range indicates strong consensus on valuation, suggesting clear investment thesis and predictable outlook.
Analyst Conviction
Strong buy conviction: High upside with tight consensus suggests compelling investment opportunity backed by analyst confidence.
Market Sentiment Insight
Monitor and evaluate: Current analyst consensus suggests limited conviction or near-term catalysts. Stay informed on company developments and reassess positioning as new information emerges.
Sagimet Biosciences Inc. Insider Positioning
During the last 12 months, insiders have purchased $1.31M and sold $1.17M worth of SGMT shares, resulting in $141K of net buying activity.
3 Months
0
0.00
0
0.00
+0
+$0
3-6 Months
0
0.00
19.7K
105.46K
-105K
-$105K
6-9 Months
0
0.00
37.7K
289.98K
-290K
-$290K
9-12 Months
244.3K
1.31M
84.5K
772.19K
+537K
+$537K
Top Buyers
Seidenberg Beth C
Director
$330K
Hoelscher Paul W.
Director
$172K
Grammer Elizabeth A
Director
$172K
Kemble George
Director
$172K
Walbert Timothy P
Director
$172K
Top Sellers
Happel David
Director, Officer: President & Ceo
$663K
Kemble George
Director, Officer: Executive Chairman
$290K
Rozek Elizabeth
Officer: Chief Legal & Admin. Officer
$113K
Martins Eduardo Bruno
Officer: Chief Medical Officer
$95K
Chauche Thierry
Officer: Chief Financial Officer
$7K
Insider Activity Analysis
Net Insider Sentiment
Moderately bullish with $141K net buying. Insiders show cautious optimism through measured share purchases.
Buy/Sell Ratio
Positive buy/sell ratio. Buying exceeds or matches selling, indicating net positive insider sentiment.
Insider Participation
5 insider buyers and 5 sellers. Equal participation suggests mixed or neutral insider views.
Insider Activity Insight
Broad-based insider buying: When multiple insiders independently decide to purchase shares, it often reflects genuine confidence rather than coordinated optics. This pattern deserves attention, especially if buying followed a price decline.
No Dividend Yield Data
SGMT has not reported any dividend yield values in the available annual periods.
sgmt Dividend History
Learning Layer
Related Guides
Build conviction on SGMT by pairing this stock hub with focused valuation guides.
Research Paths
Snapshot
Start with context, operating signals, and key market metrics.
Value Model
Stress test fair value across bear, base, and bull assumptions.
Statements
Validate revenue quality, margins, and balance sheet durability.
Earnings Call
Read management commentary and compare it with reported outcomes.
Dividends
Check payout sustainability and long-term distribution behavior.
Analyst Expectations
Review consensus spread and where estimate risk is concentrated.